12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AT13387: Phase I data

Data from 53 evaluable patients in a open-label, dose-escalating, U.S. Phase I trial showed that the MTD of once-weekly IV AT13387 was 260 mg/m 2. AT13387 produced 1 partial response in a patient with gastrointestinal stromal tumor (GIST) and 3 cases of stable disease...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >